Literature DB >> 12686096

Novel generations of influenza vaccines.

George Kemble1, Harry Greenberg.   

Abstract

Several strategies are being pursued to increase the quality and quantity of influenza vaccines that are used on an annual basis including increasing the immunogenicity of currently licensed inactivated vaccines, delivery of inactive vaccines directly to the nasal mucosa, the use of cell lines for virus production and the use of live, attenuated vaccines. In addition, modern molecular biological techniques are being used to create and evaluate new vaccine approaches. This report will briefly review these different strategies and outline some of the potential advantages and challenges associated with them.

Mesh：

Substances：

Year:  2003        PMID： 12686096     DOI： 10.1016/s0264-410x(03)00074-4

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  24 in total

Review 1.  Influenza: emergence and control.

Authors:  Aleksandr S Lipatov; Elena A Govorkova; Richard J Webby; Hiroichi Ozaki; Malik Peiris; Yi Guan; Leo Poon; Robert G Webster
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 2.  Development of universal influenza vaccines based on influenza virus M and NP genes.

Authors:  M Zheng; J Luo; Z Chen
Journal:  Infection       Date:  2013-11-01       Impact factor: 3.553

3.  Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine.

Authors:  Hye-Lim Park; Seung-Hyun Shim; Eun-Young Lee; Whajung Cho; Sooho Park; Hyun-Jung Jeon; Sun-Young Ahn; Hun Kim; Jae-Hwan Nam
Journal:  Hum Vaccin Immunother       Date:  2014-03-10       Impact factor: 3.452

4.  Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity.

Authors:  Pamela T Wong; Su He Wang; Susan Ciotti; Paul E Makidon; Douglas M Smith; Yongyi Fan; Charles F Schuler; James R Baker
Journal:  Mol Pharm       Date:  2013-12-13       Impact factor: 4.939

5.  Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge.

Authors:  Zhiyuan Wen; Ling Ye; Yulong Gao; Lei Pan; Ke Dong; Zhigao Bu; Richard W Compans; Chinglai Yang
Journal:  Antiviral Res       Date:  2009-09-20       Impact factor: 5.970

6.  Factors that may impact on immunosenescence: an appraisal.

Authors:  Joseph Ongrádi; Valéria Kövesdi
Journal:  Immun Ageing       Date:  2010-06-14       Impact factor: 6.400

7.  Metabolic effects of influenza virus infection in cultured animal cells: Intra- and extracellular metabolite profiling.

Authors:  Joachim B Ritter; Aljoscha S Wahl; Susann Freund; Yvonne Genzel; Udo Reichl
Journal:  BMC Syst Biol       Date:  2010-05-13

8.  Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

Authors:  Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang; Jadranka Bozja; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

9.  Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection.

Authors:  Marla Lay; Bernadette Callejo; Stella Chang; David K Hong; David B Lewis; Timothy D Carroll; Shannon Matzinger; Linda Fritts; Christopher J Miller; John F Warner; Lily Liang; Jeffery Fairman
Journal:  Vaccine       Date:  2009-05-09       Impact factor: 3.641

Review 10.  Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

Authors:  Christopher S Ambrose; Catherine Luke; Kathleen Coelingh
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.